PUOTI, Massimo
 Distribuzione geografica
Continente #
NA - Nord America 5.483
EU - Europa 2.036
AS - Asia 1.717
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 13
AF - Africa 9
SA - Sud America 6
Totale 9.280
Nazione #
US - Stati Uniti d'America 5.462
CN - Cina 843
UA - Ucraina 740
DE - Germania 369
SG - Singapore 348
HK - Hong Kong 311
FI - Finlandia 198
IT - Italia 175
TR - Turchia 118
GB - Regno Unito 115
IE - Irlanda 112
RU - Federazione Russa 111
PL - Polonia 100
IN - India 71
FR - Francia 45
SE - Svezia 28
CA - Canada 20
BE - Belgio 16
EU - Europa 13
AU - Australia 12
IR - Iran 9
NL - Olanda 6
AT - Austria 4
JP - Giappone 4
MU - Mauritius 4
NZ - Nuova Zelanda 4
LA - Repubblica Popolare Democratica del Laos 3
ZA - Sudafrica 3
AR - Argentina 2
BG - Bulgaria 2
BR - Brasile 2
CZ - Repubblica Ceca 2
GR - Grecia 2
HU - Ungheria 2
LT - Lituania 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
CL - Cile 1
EG - Egitto 1
ES - Italia 1
GE - Georgia 1
ID - Indonesia 1
IL - Israele 1
LK - Sri Lanka 1
LR - Liberia 1
LV - Lettonia 1
PA - Panama 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
RO - Romania 1
Totale 9.280
Città #
Woodbridge 766
Fairfield 665
Jacksonville 553
Houston 477
Ashburn 459
Ann Arbor 336
Wilmington 335
Hong Kong 311
Cambridge 310
Seattle 298
Singapore 277
Nanjing 227
Princeton 193
Chandler 177
Dublin 112
Istanbul 100
Warsaw 100
Helsinki 91
Nanchang 89
Beijing 84
Dearborn 80
Moscow 69
New York 59
Shenyang 59
Des Moines 52
San Diego 46
Changsha 43
Tianjin 42
Hebei 41
Shanghai 38
Jiaxing 36
Jinan 36
Milan 33
Lancaster 32
Brescia 30
Los Angeles 27
Washington 26
Verona 21
Kunming 19
London 19
Brussels 16
Taizhou 16
Toronto 16
Hangzhou 15
Kocaeli 15
Zhengzhou 15
Lanzhou 14
Munich 14
Leawood 13
San Francisco 13
San Mateo 13
Haikou 11
Monmouth Junction 11
Norwalk 11
Augusta 9
Ningbo 9
Ardabil 8
Melbourne 8
Guangzhou 7
Orange 6
Taiyuan 6
Fuzhou 5
Hefei 5
Auckland 4
Rome 4
Tokyo 4
Boardman 3
Charlotte 3
Grafing 3
Gunzenhausen 3
Kilburn 3
Messina 3
Ottawa 3
Rende 3
Sydney 3
Vienna 3
Vientiane 3
Athens 2
Auburn Hills 2
Bologna 2
Bratislava 2
Brno 2
Catania 2
Chicago 2
Clifton 2
Crotone 2
Dong Ket 2
Falkenstein 2
Frankfurt am Main 2
Hanover 2
Hounslow 2
Lisbon 2
Mumbai 2
Newark 2
Nuremberg 2
Oklahoma City 2
Polaveno 2
Redmond 2
Roccafranca 2
Ronciglione 2
Totale 7.115
Nome #
Use of brain MRI in manganese exposure 158
The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients 147
Phyllanthus niruri versus Placebo for Chronic Hepatitis B Virus Infection: A Randomized Controlled Trial 144
Antiretroviral drugs and liver injury. 133
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis 129
Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone 126
A meta-analysis of epidemiological studies on the combined effect of hepatitis-B and -C virus infections in causing hepatocellular carcinoma. 125
Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment 124
Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and Human Immunodeficiency Virus. 120
Alcohol and coffee drinking and smoking habit among subjects with HCV infection. 118
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. 116
Hepatitis B virus and HIV coinfection in low-income countries: unmet needs. 116
Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month 116
Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. 112
Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. 112
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. 111
Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. 107
Risk factors and clinical characteristics associated with hospitalization for community-acquired bacterial pneumonia in HIV-positive patients according to the presence of liver cirrhosis. 107
Mortality for liver disease in patients with HIV infection: a cohort study 106
Polymorphic immune restoration syndrome after effective HAART 106
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel 105
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina 105
Care of patients with hepatitis C and HIV co-infection. 103
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. 102
Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. 101
Detection of clonal T cell populations with closely related T cell receptor junctional sequences in persons at high risk for human immunodeficiency virus (HIV) infection and in patients acutely infected with HIV 101
Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C?A gender-oriented analysis. 100
Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. 97
Clinical presentation and outcome of hepatocellular carcinoma in HIV infected patients. 96
Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. 95
CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice--clinical implications for CCR5 inhibition as antiretroviral therapy. 95
Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. 95
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. 94
I data-base clinici e la sorveglianza degli eventi avversi: il progetto MASTER 93
Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis? 93
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. 93
Statements from the Taormina expert meeting on occult hepatitis B virus infection. 93
Assessment of Liver Damage with Transient Hepatic Elastography (FIBROSCAN) in patients with chronic Graft-Versus-Host Disease. 93
The burden of HIV and hepatitis C virus coinfection. 93
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? 92
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study 90
The use of molecular assays in the management of viral hepatitis. 90
Natural history of chronic hepatitis B in co-infected patients. 90
High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryoglobulinaemia 90
Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. 89
Management of hepatitis C in human immunodeficiency virus-infected patients. 89
Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy. 89
Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study 89
Hepatitis B Virus Co-infection in Human Immunodeficiency Virus- infected Subjects 88
HCV chronic hepatitis in patients with HIV: clinical management issues 88
Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis: an emerging issue. 88
Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. 88
Coinfezione HIV/HBV in Burkina Faso, Africa Occidentalele 87
Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV 86
Impact of hepatitis C virus infection on lifestyle. 85
Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 85
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. 84
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? 84
IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. 84
Prophylaxis and treatment of hepatitis B in immunocompromised patients. 83
HIV/HCV co-infection: natural history. 83
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. 83
The T-cell receptor repertoires expressed by CD4+ and CD4- large granularlymphocytes derived from the same patients suggest the persistent action of animmune-mediated selection process 81
The attributable risk of hepatocarcinoma for the Hepatitis B and C virus infections in a high-incidence area in North Italy: a case-control study. 80
Studio di coorte multicentrico per l'analisi dei fattori che influenzano la risposta alla terapia antivirale in pazienti HCV positivi: disegno dello studio. 80
Studio di coorte multicentrico per l'analisi dei fattori che influenzano la risposta alla terapia antivirale in pazienti HCV positivi: risultati del primo anno di attività. 80
Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. 80
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. 79
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients 79
Comment to the Editorial: Liver biopsy in HIV-infected pateints with chronic hepatitis C: pros and cons, by V. Soriano and J. Garcia Samaniego 78
Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? 78
Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy 78
Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort. 73
Rapid Virologic Response (RVR), IL28B Single Nucleotide Polymorphism (SNP) rs12980275 and HCV genotype are independent predictors of Sustained Virologic Response (SVR) in HIV/HCV coinfected patients treated with Pegylated Interferon and Ribavirin. 73
Co-infezione HIV-HCV e dislipidemie in corso di Highly Active Antiretroviral Therapy (HAART) 73
Studio di affidabilità sul consumo di alcol, caffè e abitudine al fumo in pazienti HCV postivi. 72
Treating hepatitis C virus in HIV patients: are side effects a real obstacle? 72
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study 72
Insulino-resistenza in pazienti HCV positivi sottoposti a trattamento antivirale in uno studio di coorte multicentrico: dati preliminari. 72
Ruolo dell'infezione occulta da virus dell'epatite B nell'evoluzione dell'epatite cronica da virus C attraverso uno studio di coorte multicentrico: dati preliminari. 71
Hepatitis viruses coinfections, antiretrovirals hepatotoxicity and risk of death in HIV infected patients: a prospective cohort study 70
Indagine sulla suscettibilità genetica nella risposta al trattamento antivirale di soggetti con epatite cronica da virus c attraverso uno studio di coorte multicentrico: disegno dello studio. 69
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection-statements of the First Italian Consensus Workshop. 68
Future research and collaboration: the “SINERGIE” project on HCV (South Italian Network for Rational Guidelines and International Epidemiology) 67
Targeted screening for viral epatiti in an italian community of 100.000 inhabitants 66
Insulin resistance is not a relevant predictor of sustaned virologic response (SVR) in chronic hepatitis c (CHC) patients treated with pegylated interferon (peg-ifn) and ribavirin. 66
Co-infezione HIV-HCV e dislipidemie in corso di terapia antiretrovirale ad elevata efficacia (HAART) 65
I Data-Base clinici e la sorveglianza degli eventi avversi alla HAART: il Progetto MASTER 61
HCV infection: pathogenesis, clinical manifestations and therapy. 61
Hepatotoxicity associated with non nucleoside reverse trasciptase inhibitors (NNRTI) in 427 adults infected with Human Immunodeficiency Virus. 60
Pathogenesis of liver damage in HCV-HIV patients. 58
Occult Hepatitis B virus and hepatocellular carcinoma: a case-control study. 58
HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3 56
Suppression of hepatitis C virus replication is maintained long term following HAART therapy, in an individual with HCV/HIV co-infection 56
Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study 56
Hepatitis C viral kinetics in HIV co-infected patients during combination treatment with interferon and ribavirin 55
Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. 54
Prevalence des marqueurs du virus de l'hepatite B et des anticorps contre le virus de l'hepatite C parmi le personnel du District sanitaire de Nanoro, Burkina Faso 53
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 53
The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug? 52
Totale 8.859
Categoria #
all - tutte 42.313
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.313


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020962 0 0 0 0 0 0 0 260 163 338 49 152
2020/20211.463 17 165 32 224 51 149 82 155 244 110 196 38
2021/2022834 52 128 1 46 3 46 40 55 35 119 86 223
2022/2023654 112 8 10 31 49 207 0 70 90 7 31 39
2023/2024786 42 16 71 81 45 141 31 36 199 14 2 108
2024/2025813 8 4 7 237 213 158 156 30 0 0 0 0
Totale 9.385